Skip to main content
SpringerLink
Log in

Phosphodiesterase type 5 inhibitors and endothelial function

  • Published:
Current Sexual Health Reports Aims and scope Submit manuscript

Abstract

Erectile dysfunction (ED) and endothelial dysfunction are common in individuals with multiple cardiovascular risk factors (CRFs) and are longitudinal predictors of cardiovascular events. ED is associated with systemic endothelial cell activation/dysfunction independent from CRFs or from diffuse, unrecognized vascular damage. The pathogenesis of endothelial dysfunction and ED is intimately linked through increased expression and activation of endothelial nitric oxide (NO) synthase and the subsequent physiologic actions of NO. Reduced biologic activity of endothelium-derived NO links human atherosclerosis to ED and underscores the role of altered endothelium in the pathogenesis of both conditions. ED may be the only clinical marker of systemic endothelial damage that is associated with a documented future risk of acute cardiovascular events. Searching for ED might be relevant in men with CRFs and no other clinical atherosclerosis in order to identify patients who could benefit from phosphodiesterase type 5 inhibitors to reduce their cardiovascular risk while treating ED.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Andersson KE, Becher E, Hendry B, et al.: Recommendations of the First International Consultation on Erectile Dysfunction. In Erectile Dysfunction. First International Consultation on Erectile Dysfunction—July 1–3, 1999, Paris. Edited by Jardin A, Wagner G, Khoury S, et al.: Plymouth: Plymbridge Distributors Ltd; 1999: 711–713.

    Google Scholar 

  2. Aytac IA, McKinlay JB, Krane RJ: The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. Br J Urol Int 1999, 84:450–456.

    Google Scholar 

  3. Kannel WB, McGee DL: Diabetes and cardiovascular disease: the Framingham study. JAMA 1979, 241:2035–2038.

    Article  PubMed  CAS  Google Scholar 

  4. Laakso M, Haffner SM, Leto S, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229–234.

    Article  PubMed  Google Scholar 

  5. Grundy SM, Benjamin IJ, Burke GL, et al.: Diabetes and cardiovascular disease: a statement for health professionals from the American Heart Association. Circulation 1999, 100:1134–1146.

    PubMed  CAS  Google Scholar 

  6. Vitale C, Mercuro G, Cornoldi A, et al.: Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med 2005, 258:250–256.

    Article  PubMed  CAS  Google Scholar 

  7. Aversa A, Pili M, Fabbri A, et al.: Erectile dysfunction: expectations beyond phosphodiesterase type 5 inhibition. J Endocrinol Invest 2004, 27:192–206.

    PubMed  CAS  Google Scholar 

  8. Rendell MS, Rajfer J, Wicker PA, et al.: Sildenafil for the treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999, 281:421–426.

    Article  PubMed  CAS  Google Scholar 

  9. Schachinger V, Britten MB, Zeiher AM: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000, 101:1899–1906.

    PubMed  CAS  Google Scholar 

  10. Suwaidi JA, Hamasaki S, Higano ST, et al.: A long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000, 101:948–954.

    PubMed  CAS  Google Scholar 

  11. Aversa A, Bruzziches R, Vitale C, et al.: Chronic sildenafil in men with diabetes and erectile dysfunction. Expert Opin Drug Metab Toxicol 2007, 3:451–464.

    Article  PubMed  CAS  Google Scholar 

  12. Bruzziches R, Greco EA, Pili M, et al.: Redefining the role of long-acting phosphodiesterase inhibitor tadalafil in the treatment of diabetic erectile dysfunction. Curr Diab Rev 2007, In press.

  13. Andersson KE, Wagner G: Physiology of penile erection. Physiol Rev 1995, 75:191–236.

    PubMed  CAS  Google Scholar 

  14. Traish AM, Guay AT: Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence. J Sex Med 2006, 3:382–407.

    Article  PubMed  CAS  Google Scholar 

  15. Burnett AL: Nitric oxide in the penis: physiology and pathology. J Urol 1997 157:320–324.

    Article  PubMed  CAS  Google Scholar 

  16. Hurt KJ, Musicki B, Palese MA, et al.: Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection. Proc Natl Acad Sci USA 2002, 99:4061–4066.

    Article  PubMed  CAS  Google Scholar 

  17. Burnett AL: Novel nitric oxide signaling mechanisms regulate the erectile response. Int J Impot Res 2004, 16:S15–S19.

    Article  PubMed  CAS  Google Scholar 

  18. Kharband RK, Deanfield JE: Functions of the healthy endothelium. Coron Artery Dis 2001, 12:485–491.

    Article  Google Scholar 

  19. Sagripanti A, Carpi A: Antithrombotic and prothrombotic activities of the vascular endothelium. Biomed Pharmacother 2000, 54:107–111.

    Article  PubMed  CAS  Google Scholar 

  20. Panes J, Perry M, Granger DN: Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention. Br J Pharmacol 1999, 126:537–550.

    Article  PubMed  CAS  Google Scholar 

  21. Vane JR, Anggard EE, Botting RM: Regulatory functions of the vascular endothelium. N Engl J Med 1990, 323:27–36.

    Article  PubMed  CAS  Google Scholar 

  22. Duffy SJ, Tran BT, New G, et al.: Continuous release of vasodilator prostanoids contributes to regulation of resting forearm blood flow in humans. Am J Physiol 1998; 274:H1174–H1183.

    PubMed  CAS  Google Scholar 

  23. Maas R, Schwedhelm E, Albsmeier J, et al.: The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function. Vasc Med 2002, 7:213–225.

    Article  PubMed  Google Scholar 

  24. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801–809.

    Article  PubMed  CAS  Google Scholar 

  25. Russell S, Nehra A: The physiology of erectile dysfunction. Herz 2003, 28:277–283.

    PubMed  Google Scholar 

  26. Brunner H, Cockcroft JR, Deanfield J, et al.: Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005, 23:233–246.

    Article  PubMed  CAS  Google Scholar 

  27. Bonetti PO, Lerman LO, Lerman A, et al.: Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003, 23:168–175.

    Article  PubMed  CAS  Google Scholar 

  28. Farouque HMO, Meredith IT: The assessment of endothelial function in humans. Coron Artery Dis 2001, 12:445–454.

    Article  PubMed  CAS  Google Scholar 

  29. Vita JA, Keaney JF Jr: Endothelial function: a barometer for cardiovascular risk? Circulation 2002, 106:640–642.

    Article  PubMed  Google Scholar 

  30. Watts GF, Chew KK, Stuckey BGA: The erectile-endothelial dysfunction nexus: new opportunities for cardiovascular risk prevention. Nature 2007, 4:263–273.

    CAS  Google Scholar 

  31. Boger RH: The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 2003, 59:824–833.

    Article  PubMed  CAS  Google Scholar 

  32. Valkonen VP, Paiva H, Salonen JT, et al.: Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001, 358:2127–2128.

    Article  PubMed  CAS  Google Scholar 

  33. Cooke JP: ADMA: its role in vascular disease. Vasc Med 2005, 10(Suppl 1):S11–S17.

    Article  PubMed  Google Scholar 

  34. Cooke JP, Dzau VJ: Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 1997, 48:489–509.

    Article  PubMed  CAS  Google Scholar 

  35. Browne D, Meeking D, Shaw K et al.: Endothelial dysfunction and pre-symptomatic atherosclerosis in type 1 diabetes—pathogenesis and identification. Br J Diabetes Vasc Dis 2003, 3:27–34.

    Article  Google Scholar 

  36. Elesber AA, Solomon H, Lennon RJ, et al.: Coronary endothelial dysfunction is associated with erectile dysfunction and elevated asymmetric dimethylarginine in patients with early atherosclerosis. Eur Heart J 2006, 27:824–831.

    Article  PubMed  CAS  Google Scholar 

  37. Baumhakel M, Werner N, Bohm M, et al.: Circulating endothelial progenitor cells correlate with erectile function in patients with coronary heart disease. Eur Heart J 2006, 27:2184–2188.

    Article  PubMed  CAS  Google Scholar 

  38. Kielstein JT, Frolich JC, Haller H, et al.: ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease? Nephrol Dial Transplant 2001, 16:1742–1745.

    Article  PubMed  CAS  Google Scholar 

  39. Boger RH: Asymmetrical methylarginine (ADMA) as a cardiovascular risk factor: epidemiological and prospective data. Dtsch Med Wochenschr 2004, 129:820–824.

    Article  PubMed  CAS  Google Scholar 

  40. Schiel R, Franke S, Busch M, et al.: Effect of smoking on risk factors for cardiovascular disease in patients with diabetes mellitus and renal insufficiency. Eur J Med Res 2003, 8:283–291.

    PubMed  CAS  Google Scholar 

  41. Lu TM, Ding YA, Lin SJ, et al.: Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 2003, 24:1912–1919.

    Article  PubMed  CAS  Google Scholar 

  42. Wierzcicki AS, Solomon H, Lumb PJ, et al.: Asymmetrical dimethylarginine levels correlate with cardiovascular risk factors in patients with erectile dysfunction. Atherosclerosis 2006, 185:421–425.

    Article  CAS  Google Scholar 

  43. Fonseca V, Jawa A: Endothelial and erectile dysfunction, diabetes mellitus, and the metabolic syndrome: common pathways and treatments? Am J Cardiol 2005, 96:13M–18M.

    Article  PubMed  Google Scholar 

  44. Cersosimo E, DeFronzo RA: Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev 2006, 22:423–436.

    Article  PubMed  CAS  Google Scholar 

  45. Kim JA, Montagnani M, Koh KK, et al.: Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006, 113:1888–1904.

    Article  PubMed  Google Scholar 

  46. Gonzalez MA, Selwyn AP: Endothelial function, inflammation, and prognosis in cardiovascular disease. Am J Med 2003, 115:99S–106S.

    Article  PubMed  CAS  Google Scholar 

  47. Bank AJ, Billups KL, Kaiser DR, et al.: Relation of C-reactive protein and other cardiovascular risk factors to penile vascular disease in men with erectile dysfunction. Int J Imp Res 2003, 15:231–236.

    Article  CAS  Google Scholar 

  48. Bocchio M, Scarpelli P, Necozione S, et al.: Intima-media thickening of common carotid arteries is a risk factor for severe erectile dysfunction in men with vascular risk factors but no clinical evidence of atherosclerosis. J Urol 2004, 171:1601–1604.

    Article  PubMed  Google Scholar 

  49. Goldstein I, Lue TF, Padma-Nathan H, et al.: Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998, 338:1397–1404.

    Article  PubMed  CAS  Google Scholar 

  50. Ballard SA, Gingell CJ, Tang K, et al.: Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998, 159:2164–2171.

    Article  PubMed  CAS  Google Scholar 

  51. Beavo JA: Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995, 75:725–748.

    PubMed  CAS  Google Scholar 

  52. Ceriello A, Assaloni R, Da Ros R, et al.: Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 2005, 111:2518–2524.

    Article  PubMed  CAS  Google Scholar 

  53. Behr-Roussel D, Gorny D, Mevel K, et al.: Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. Eur Urol 2005, 47:87–91.

    Article  PubMed  CAS  Google Scholar 

  54. Ayala JE, Bracy DP, Julien BM, et al.: Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes 2007, 56:1025–1033.

    Article  PubMed  CAS  Google Scholar 

  55. Pegge NG, Twomey AM, Vaughton K, et al.: The role of endothelial dysfunction in the pathophysiology of erectile dysfunction in diabetes and in determining response to treatment. Diabet Med 2006, 23:873–878.

    Article  PubMed  CAS  Google Scholar 

  56. Rosano GM, Aversa A, Vitale C, et al.: Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005, 47:214–222.

    Article  PubMed  CAS  Google Scholar 

  57. Roizenblatt S, Guilleminault C, Poyares D, et al.: A double-blind, placebo-controlled, crossover study of sildenafil in obstructive sleep apnea. Arch Intern Med 2006, 166:1763–1767.

    Article  PubMed  CAS  Google Scholar 

  58. McMahon C: Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on demand tadalafil. J Sex Med 2004, 1:292–300.

    Article  PubMed  CAS  Google Scholar 

  59. Aversa A, Greco E, Bruzziches R, et al.: Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res 2007, 19:200–207.

    Article  PubMed  CAS  Google Scholar 

  60. Proietti M, Aversa A, Letizia C, et al.: Erectile dysfunction in systemic sclerosis: effects of long-term inhibition of phosphodiesterase type-5 on erectile function and plasma endothelin-1 levels. J Rheumatol 2007, 34:1712–1717.

    PubMed  CAS  Google Scholar 

  61. Jannini EA, Screponi E, Carosa E, et al.: Lack of sexual activity from erectile dysfunction is associated with a reversible reduction in serum testosterone. Int J Androl 1999, 22:385–392.

    Article  PubMed  CAS  Google Scholar 

  62. Greco EA, Pili M, Bruzziches R, et al.: Testosterone: estradiol ratio changes associated with long-term tadalafil administration: a pilot study. J Sex Med 2006, 3:716–722.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dip.to Fisiopatologia Medica, Room 37, Viale Policlinico 155, 00161, Rome, Italy

    Antonio Aversa

Authors
  1. Antonio Aversa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roberto Bruzziches
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonio Aversa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aversa, A., Bruzziches, R. Phosphodiesterase type 5 inhibitors and endothelial function. Curr sex health rep 4, 157–162 (2007). https://doi.org/10.1007/s11930-007-0020-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11930-007-0020-3

Keywords

Search

Navigation